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Simple Summary: The main target of mesenchymal stem cell therapy in horses has long been
the locomotor system, because these athletic animals commonly suffer from tendon and joint le-
sions. Originally, mesenchymal stem cells were thought to act by just differentiating into the cells
of the injured tissue. However, these cells are also able to regulate and stimulate the body’s own
repair mechanisms, opening the door to many applications in inflammatory and immune-mediated
disorders in both animals and humans. In horses, beyond their traditional application in the muscu-
loskeletal system, these cells have been studied for ophthalmologic pathologies such as corneal ulcers
or immune-mediated processes, and for reproductive disorders such as endometritis/endometrosis.
Their potential has been explored for equine pathologies very similar to those affecting people, such
as asthma, metabolic syndrome, aberrant wound healing, or endotoxemia, as well as for equine-
specific pathologies such as laminitis. Current evidence is still preliminary, and further research is
needed to clarify different aspects, although research performed so far shows the promising potential
of mesenchymal stem cells to treat a wide variety of equine pathologies, some of which are analogous
to human disorders. Therefore, advancements in this path will be beneficial for both animals and
people.
Abstract: The differentiation ability of mesenchymal stem cells (MSCs) initially raised interest for
treating musculoskeletal injuries in horses, but MSC paracrine activity has widened their scope for
inflammatory and immune-mediated pathologies in both equine and human medicine. Furthermore,
the similar etiopathogenesis of some diseases in both species has advanced the concept of “One
Medicine, One Health”. This article reviews the current knowledge on the use of MSCs for equine
pathologies beyond the locomotor system, highlighting the value of the horse as translational model.
Ophthalmologic and reproductive disorders are among the most studied for MSC application.
Equine asthma, equine metabolic syndrome, and endotoxemia have been less explored but offer an
interesting scenario for human translation. The use of MSCs in wounds also provides a potential
model for humans because of the healing particularities in both species. High-burden equine-
specific pathologies such as laminitis have been suggested to benefit from MSC-therapy, and MSC
application in challenging disorders such as neurologic conditions has been proposed. The available
data are preliminary, however, and require further development to translate results into the clinic.
Nevertheless, current evidence indicates a significant potential of equine MSCs to enlarge their range
of application, with particular interest in pathologies analogous to human conditions.
Keywords: One Medicine; mesenchymal stem cells; immune-mediated disorders; ophthalmology;
reproduction; equine asthma; equine metabolic syndrome; wounds; laminitis; neurologic disorders
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1. Introduction
The equine industry is a sector of great economic importance, mainly due to the
sporting dedication of the horse. Thus, musculoskeletal conditions have a great relevance
in these animals. The limited healing capacity of ligaments, tendons, and cartilage have
led to the interest in advanced biological therapies [1] aimed at restoring the structure
and functions of tissues or organs using the own mechanisms of the body [2], of which
mesenchymal stem cells (MSCs) are of particular relevance.
Initially, MSC therapeutics were predicated to be based on their ability to differen-
tiate into cells of the appropriate tissue type, and thus to directly stimulate regeneration
of the damaged structures. However, it has been shown that MSCs exert their effects
mainly through the secretion of a wide range of bioactive molecules [1], which signifi-
cantly increases the scope for their therapeutic applications. Actually, the main focus on
musculoskeletal application in equine practice is in contrast with human medicine, where
MSC therapies are primarily focused on immune-mediated, inflammatory, and ischemic
diseases [3].
Even though musculoskeletal pathologies are among the most frequent in horses, the
alteration of other systems is also of great relevance provided their economic and welfare
impact [4]. The treatment of some of these pathologies presents important limitations
owing to different factors, such as horse anatomy and healing physiology in the case of
wounds [5], or intrinsic characteristics of immune-based pathologies such as asthma, where
only palliative treatments are available [6]. Thus, the range of therapeutic mechanisms
elicited by equine MSCs could extend their application beyond the locomotor system. More-
over, numerous naturally occurring diseases in both animals and humans (developmental,
infectious, autoimmune, or allergic) have similar pathophysiological bases [7].
This review aims at revising the current knowledge on the use of MSCs for equine
pathologies beyond the locomotor system, including ophthalmic and reproductive patholo-
gies, equine metabolic syndrome, equine asthma, wounds, laminitis, neurological disorders,
and systemic inflammatory response syndrome, highlighting the value of the horse as a
translational model for developing novel treatments that could benefit both animals and
humans.
1.1. “One Medicine, One Health”: The Role of the Horse
In comparison with small animals such as rodents, large species such as horses better
resemble the anatomy and physiology of humans, and their greater lifespan allows for
longer-term follow-up. Several organizations such as the European Medicines Agency,
the U.S. Food and Drug Administration, and the International Society for Stem Cell Re-
search are recommending the use of large animal models to evaluate the efficacy, durability,
dose response, and safety of advanced therapeutic medicinal products [8]. Horses are al-
ready recognized as models for several human diseases, including metabolic syndrome [9],
asthma [10], musculoskeletal diseases [11,12], melanoma [13], or autoimmune uveitis [14].
Moreover, other equine conditions may also serve as models, including infectious dis-
eases [15], fertility disorders [16], and even depression and mental conditions [17,18].
All of this led to the development of the “One Health, One Medicine” approach,
which, according to the World Health Organization, promotes a vision of the health of
humans, animals and the environment as a coherent system, and presumes that diseases in
humans and animals require analogous therapeutic approaches [19]. Hence, progress in
animal models is mutually beneficial for animals, researchers, and human and veterinary
patients. Importantly, the rapid advancement of regenerative medicine in the horse makes
this species particularly relevant for translational research [20].
1.2. Properties of Mesenchymal Stem Cells
Mesenchymal stem cells are adult and multipotent stem cells of mesodermal origin,
which have raised interest in the field of regenerative medicine due to their unique biologi-
cal properties [21]. Equine MSC characterization is based on the recommendations of the
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International Society for Cell Therapy (ISCT) set for human MSCs, which include cellu-
lar plastic adherence, expression of the surface markers cluster of differentiation (CD)90,
CD105 and CD73, and the lack of expression of CD45, CD34, CD14 or CD11b, CD79a or
CD19 and human leukocyte antigen (HLA) class II. In addition, these cells must be able
to differentiate at least into osteoblasts, adipocytes and chondrocytes in vitro [22]. Equine
MSCs meet the set criteria of plastic adherence and multipotency, but variably express
different surface markers depending on tissue source [23,24].
In equine medicine, MSCs are often the choice for advanced therapies, due to their
ease of isolation and culture, their multipotency, and their ability to migrate to damaged
tissues [25]. The mechanisms of action through which MSCs exert their effects have not
been fully characterized [21]. Initially, it was thought that MSCs differentiated directly
into cells of the affected tissue or enhanced the activity of resident cells [3], although it has
been reported that MSCs can act indirectly by secreting immunomodulatory and bioactive
factors [22–24,26,27].
These paracrine effects can be divided into immunomodulatory, anti-scarring, chemoat-
tractant and trophic effects, which can be further subdivided into anti-apoptotic, supportive
(stimulation of mitosis, proliferation and differentiation of precursors) and angiogenic.
The number of molecules known to mediate the paracrine action of MSCs increases every
day [28]; thus indicating that there is a substantial potential to harness these properties to
treat several medical conditions in horses.
For example, MSCs secrete different chemokines that recruit and regulate the func-
tion of several cell types, as well as growth factors such as vascular endothelial growth
factor (VEGF), hepatocyte growth factor (HGF) or the leukemia inhibitory factor (LIF) that
promote survival and stimulate the proliferation of resident cells. Some of these growth
factors, such as VEGF, also elicit pro-angiogenic effects of great importance, because the
restoration of blood supply is essential for the recovery of damaged tissues [25].
In addition, MSCs secrete different cytokines and mediators such as interleukin (IL)-6
and 10, prostaglandin E-2 (PGE-2), transforming growth factor (TGF-β), or nitric oxide
(NO), which elicit immunomodulatory actions such as inhibiting the proliferation of T
lymphocytes [29], prevent lysis mediated by cytotoxic T cells [30], suppress the activation
of natural killer (NK) cells [31] and macrophages [32], or modulate B cell proliferation [33].
2. Applications of Equine MSCs in Ophthalmology
The corneal epithelium contains limbal stem cells (LSCs), whose deficiency may greatly
affect corneal transparency and integrity of the ocular surface [34]. Mesenchymal stem cells can
differentiate into corneal epithelial cells both in vitro and in vivo in rabbits [35]. In addition,
MSC paracrine activity can reduce oxidative stress and inhibit the release of pro-inflammatory
cytokines, thereby reducing corneal inflammation and neovascularization [36,37]. The in vivo
ophthalmologic studies presented here are summarized in Table 1.
2.1. Corneal Ulcers and Ulcerative Keratitis
Horses are more prone to corneal damage than other species because of their large-
sized eyes placed laterally and prominently [38], and the active movements of their head
which favors exposure to bacterial or fungal contamination [39]. Some corneal ulcers can
be very severe due to protease activity and can lead to vision loss. The therapeutic strategy
should be aimed at eradicating the infection and limiting cornea destruction, in order to
control pain and minimize scar formation [40]. Current therapies include topical antibiotics,
anti-proteases, and mydriatic or cycloplegic drugs [41], but the typically associated pain
makes repeated local administration difficult.
The wound healing capacity of equine autologous bone marrow-derived MSCs (BM-
MSCs) and their supernatant (MSC-Sp) was evaluated in vitro using a scratch assay in
corneal fibroblasts. The significant decrease in the scratch area after exposure to either
MSCs or MSC-Sp suggested their potential to improve corneal healing. Interestingly, the
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use of MSC-Sp may provide a stem cell-derived but cell-free product that could be more
easily stored and applied [42].
Regarding in vivo studies, in one case of bacterial ulcerative keratitis unresponsive to
conventional therapies, a single dose of autologous peripheral blood-derived stem cells
(PB-SCs) was applied both systemically (intravenously (IV), jugular vein) and in transverse
facial artery. In addition, local application was performed three times a day for seven days.
Three months later, the ulcer was almost unnoticed and the clinical signs of inflammation,
pain and irritation disappeared [43]. Similar results were observed in another case of
bacterial ulcerative keratitis and in three cases of corneal ulcers treated with IV and local
administration of autologous PB-SCs [40].
2.2. Equine Recurrent Uveitis
Equine recurrent uveitis (ERU) is a spontaneous and immune-mediated disorder
characterized by recurrent episodes of intraocular inflammation separated by periods of
remission [44]. The exact pathophysiology of ERU is not clear, although it is thought
that Leptospira interrogans can be implicated by initiating an infection that leads to ocular
immune privilege breakdown [45]. The subsequent immune response involves cytokines
and chemokines that activate helper T cells (Th), and Th17-associated cytokines seem
to play a role [46]. Currently, there is no cure, and treatment is focused on preserving
vision, alleviating pain, and limiting the recurrence of episodes by using mydriatics and
anti-inflammatory drugs. The end stage of the disease in the majority of affected horses is
blindness [44].
Mesenchymal stem cells are effective at reducing immune cell activation in vitro in
many species, making them a potential therapeutic option for ERU [47]. It has been shown
in several mammals, such as cats, dogs and horses, that MSCs can induce a switch from
pro-inflammatory to regulatory T cell subsets when applied in immune diseases [47–49].
The same has been suggested for ERU in an in vitro assay in which lymphocytes from ERU-
affected horses were co-cultured with adipose-derived MSCs (AT-MSCs) [50]. However,
to the best of the authors’ knowledge, there is no literature on controlled equine clinical
studies employing MSCs in ERU except for a brief mention in the study of Saldinger et al.,
which stated satisfactory treatment of three cases (unpublished data).
Interestingly, ERU closely resembles human autoimmune uveitis regarding clinical
and immune pathological features, including the same autoantigens involved and the
remitting-relapsing onset of the disease. Therefore, ERU has been suggested as a reliable
spontaneous model to study the histopathological changes and the inflammatory processes
in uveitis [14,51]; thus, therapeutic advancements in ERU and human uveitis can be
mutually beneficial.
2.3. Equine Immune Mediated Keratitis
Equine immune mediated keratitis (IMMK) is a generic term used to describe a het-
erogeneous group of chronic, non-ulcerative corneal opacities accompanied by intraocular
inflammation. The etiopathogenesis is unknown, but seems to be related with dysregulated
immune responses involving a complex cytokine cascade and amplified pro-inflammatory
response [41]. Long-term topical anti-inflammatory and immunosuppressive therapy is
the main management protocol, although it does not offer a definitive solution and can be
challenging to maintain with low owner compliance or poor response to treatment [52].
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Table 1. Ophthalmology in vivo studies using stem cells in horses. Peripheral blood stem cells (PB-SCs), phosphate-buffered saline (PBS), equine recurrent uveitis (ERU), bone
marrow-derived mesenchymal stem cells (BM-MSCs), immune-mediated keratitis (IMMK), intravenous (IV).







(one case): 20-year-old gelding,
with bacterial (Pseudomonas
aeruginosa) ulcerative keratitis,
resistant for 6 months against
conventional therapies and
surgical intervention.
A one-time injection in
the jugular vein (125 ×
103 PB-SCs in 5 mL PBS)
and in transverse facial
artery (125 × 103
PB-MSCs in 5 mL PBS)
+ local application (eye
drops formulation, 500
× 103 PB-SCs in 5 mL
PBS) 3 times/day, 7
days.
• 2 weeks: inflammation and
tear flow decreased; ulcer
size reduced





Single case with no control
Cells used not expanded and not
fully characterized as MSCs
After 7 days, eye drop application
was stopped because the cell
suspension appeared cloudy,
probably because of cell death.







Naturally occurring pathology (4
cases)
• Case 1: 20-year-old gelding
with bacterial (Pseudomonas
aeruginosa) ulcerative




• Case 2: 7-year-old mare with
a corneal ulcer treated for 2
weeks and IMKK treated for
a year
• Case 3: 12-year-old gelding
with traumatic corneal ulcer
treated for 6 months
• Case 4: 13-year-old gelding
with ERU-derived corneal






• 2 weeks: inflammation and
lacrimation decreased; ulcer
size reduced and stable.
• 3 months: eye ulcer reduced,
inflammation stable, pain
and irritation disappeared.
• >3 months: eye ulcer
disappeared
Case 2:
• 1 month: no signs of relapse
Case 3:
• 2 weeks: ulcer significantly
reduced
• 1 month: deposit of melanin
(scarring effects)
Case 4:
• 2 months: corneal ulcer
completely disappeared
Low number of cases and with
corneal ulcers of different origins
Absence of control group, but
animals unresponsive to previous
treatments
Cells used not expanded and not
fully characterized as MSCs
Number of PB-SCs administrated
not stated
Administration route and protocol
unclear at some points
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Table 1. Cont.







(one case): 7-year-old mare,
poorly responsive to traditional






• 1 month: no signs of relapse
• 3 months: complete recovery
of clinical signs
A single case with no control
group







(4 cases): unilateral IMMK poorly
responsive to traditional medical
treatments
• Case 1: 9-year-old gelding
with midstromal keratitis
• Case 2: 12year-old mare with
superficial to midstromal
keratitis
• Case 3: 9-year-old gelding
with midstromal keratitis
• Case 4: 10-year-old gelding
with midstromal keratitis
Subconjunctival injection
(15 × 106 MSCs in 1 mL
PBS) every 3–4 weeks for
1–5 injections
• Case 1: 1 single
injection
• Case 2: 3 injections
every 3–40 weeks
• Case 3: 3 injections
every 3–6 weeks
• Case 4: 3 injections
every 3 weeks
Cases 2 and 3 received 1
and 2 additional
injections, respectively




• No relapse for average 1
year.
• Case 1, 2 and 3: Resolution
of fibrosis and
neovascularization
• Case 4: Enucleation due to
disease worsening and
discomfort
Low number of cases with no




Variability in the administration
protocol
Additional topical treatments in
some case in conjunction with the
BM-MSCs (cyclosporine,
bromfenac, diclofenac or flunixin
meglumine)
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Due to the immunomodulatory action of MSCs, these have been suggested as potential
therapeutic tools. One case of IMMK was reported to have a positive response after
two intravenous injections of autologous PB-SCs and local instillation, without signs
of relapse [40]. In another study involving four horses with IMMK unresponsive to
conventional treatment, subconjunctival injection of autologous BM-MSCs (1–5 injections
every 3–4 weeks) was tested along with usual treatment. Three horses had a positive clinical
response, as demonstrated by decreased corneal opacity, diminished neovascularization,
and improvement in surface irregularity [53].
The limitations of most in vivo ophthalmologic studies include a small sample and
variability in patient selection, along with lack of a control group. Nevertheless, all cases
were poorly responsive to medical management and showed improvement after MSC ther-
apy. The administration protocol, including route, number of applications, and duration
of the treatment, as well as medical management before and during MSC therapy, varied
significantly. Regarding the route of administration, the subconjunctival space is relatively
common for ocular medications and provides high drug concentration to the cornea and
anterior structures for prolonged periods [54]; therefore, it could represent a suitable ap-
proach for local MSC administration that avoids repeated manipulation of the painful eye
for local instillation, which also poses the problem of prolonged storage [43]. Other delivery
systems include local intra-arterial injection in order to reach the internal structures of the
eye, and contact lenses seeded with MSCs have been used in other models [55]. Further
research based on controlled studies and standardized protocols supported by distribution
assays is needed to demonstrate the benefits of such treatments and implement its use in
clinical practice.
3. Applications of Equine MSCs in Reproduction
Due to the MSC regenerative and immunomodulatory properties, these might be used
to treat damaged reproductive tissues, as has been proposed in different animal models,
such as rats [56]. Table 2 summarizes the in vivo reproduction-related studies discussed
below.
3.1. Endometritis
Endometritis is the infection and/or inflammation of the endometrium, and con-
stitutes the main cause of subfertility and is the third most common disease affecting
horses [57]. Repeated inflammation of the endometrium can lead to endometrosis, a
chronic state characterized by fibrosis with glandular alterations [58]. Both persistent
breeding-induced endometritis (PBIE) and endometrosis are of pivotal importance for
reproductive health in mares.
3.1.1. Equine Persistent Breeding-Induced Endometritis
Persistent breeding-induced endometritis is an acute inflammatory response of the
endometrium to semen, linked to an incapability of the uterus to remove bacteria, sper-
matozoa, and inflammatory exudate post-breeding. This disease affects broodmares of all
breeds, leading to reproductive inefficiency and important economic losses [59]. Traditional
therapeutic modalities lack sufficient effectivity, which along with increasing antibiotic-
resistances, has led to the development of alternative therapies such as MSCs [60], because
of their engraftment and immunomodulatory abilities.
Studies in healthy mares have provided a first insight into the effects of MSCs on
reproductive tissues. Autologous MSCs isolated from endometrial biopsies harvested
from healthy mares were infused into both uterine horns during the early diestrus to
avoid ready elimination from the uterine lumen. Endometrial mesenchymal stem cells
(eMSCs) were detected in the uterine lumen up to 24 h after infusion, but they did not
engraft into the endometrium. Moreover, eMSCs effectively attenuated the inflammatory
response produced by the uterine infusion itself [61]. Another study showed that allo-
genic BM-MSCs infused into the uterus 24 h before insemination modulated the uterine
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inflammatory response in healthy mares [62]. Subsequently, PBIE was induced in nine
healthy mares which received intrauterine instillation of allogeneic AT-MSCs or eMSCs.
The MSC administration significantly reduced inflammation regardless of the origin of the
cells, but their engraftment after one month was limited, suggesting that their function in
this context is preferentially exerted by paracrine mechanisms [63].
3.1.2. Endometrosis
Endometrosis is characterized by periglandular and/or stromal endometrial fibrosis,
including glandular alterations within fibrotic foci. The etiology is not fully elucidated,
but it seems to be age-related [64]. The endometrial changes caused by this disease are
irreversible, and therapeutic management is challenging [65].
In an ex vivo model, endometrial biopsies from healthy and pathological mares were
exposed to allogeneic AT-MSCs, which were able to infiltrate both the periglandular space
and single glands of endometrosis-affected tissue [66]. In an in vivo study, autologous
BM-MSCs were injected directly into the uterus using a catheter in mares with subfertility
history and degenerated endometrium to assess safety in pathological conditions, observing
no clinical alterations, histological changes, or endometrial edema [67]. These studies
suggest the feasibility and safety of endometrial injection of MSCs as a new therapeutic
approach for uterine disorders.
Another study reported that allogeneic AT-MSCs infused in the uterine lumen of six
endometrosis-affected mares effectively homed into both the glandular and non-glandular
endometrium when delivered by a simple technique, similar to that used for artificial
insemination [68]. A continuation of this study showed histological improvement of
endometrosis after infusing allogeneic AT-MSCs. The authors suggested that multiple
mechanisms, including homing to fibrotic areas and increased epithelial cell proliferation,
might mediate the anti-scarring effects observed [69]. Furthermore, amniotic membrane-
derived MSCs may improve the endometrial cell replenishment when scarcity or low
proliferation of endometrial cells is associated with pregnancy failure [70].
Compared to BM-MSCs, eMSCs have a higher ability to differentiate into smooth
muscle [71], and display robust immunomodulatory [72] and migratory properties [73].
Moreover, eMSCs can be collected from simple endometrial biopsies, which can be safely
and repeatedly obtained, thus suggesting a novel source of therapeutic cells for inflamma-
tory conditions of the uterus [74].
3.2. Ovarian Diseases
Intra-ovarian injection of allogeneic BM-MSCs to treat ovarian dysfunction in old
mares has been suggested in one study. Although there were no side effects, MSC injection
was not associated with significant changes in follicle number, oocyte recovery and matu-
ration rate, or blastocyst rate [75]. This contrasts with MSC beneficial effects observed in
chemotherapy-damaged ovaries in other species [76,77], but these data should be extended
to be conclusive, because to the best of the authors’ knowledge, there are no further studies
exploring this possibility.
3.3. Testicular Diseases
Testicular disorders are characterized by altered or suppressed activity leading to
important reproductive issues in stallions and consequent economic impacts [78]. Im-
munomodulatory, anti-inflammatory, and anti-apoptotic effects of MSCs, as well as their
ability to migrate to injured tissues, support their potential to treat testicular disorders, as
suggested in an induced testicular torsion model in rats [79]. One in vivo study evaluated
the intratesticular injection of allogeneic BM-MSCs in healthy stallions. The absence of clini-
cal abnormalities and altered semen parameters suggested that this is a safe procedure [80],
although further studies are required to test their therapeutic potential.
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Table 2. In vivo studies using mesenchymal stem cells in equine reproduction. Endometrial mesenchymal stromal cells (eMSCs), phosphate-buffered saline (PBS), polymorphonuclear
neutrophils (PMNs), bone marrow mesenchymal stem cells (BM-MSCs), anti-Müllerian hormone (AMH), autologous conditioned serum (ACS), lactate ringer (LR), intrauterine (IU),
post-breeding induced endometritis (PBIE), adipose tissue MSCs (AT-MSCs), artificial insemination (AI), fetal bovine serum (FBS), dimethyl sulfoxide (DMSO), interleukin 6 (IL-6), tumor
necrosis factor alpha (TNFα), intracytoplasmic sperm injection (ICSI).










labelled eMSCs and follow-up:
• Uterine cytology
• Tracking of eMSCs in
peripheral blood
• Tracking of eMSCs in uterus
(lumen and endometrial
biopsies)
7 healthy cycling mares, 4–7 years
old.Four of these mares were used
as controls, two estrous cycles
before the eMSC infusion cycle.
15 × 106 eMSCs in 1 mL or PBS
infused into each uterine horn
during early diestrus (day 4 after
ovulation).
Mild inflammatory reaction after
infusion was attenuated by
eMSCs (percentage of PMNs
lower in eMSC than PBS-infused
mares at 6h)
eMSCs detected in the uterine
horn lumen for up to 24 h after
infusion but did not migrate into
healthy endometrium.
eMSCs were not found in the




and cells persist in the
uterine lumen for up to
24 h after infusion, but
do not engraft into
healthy endometrium at
that time.
PBIE Ferris et al.,2014 [62]
Allogeneic
BM-MSCs
Evaluate the ability of ACS,
BM-MSCs or dexamethasone to
modulate the inflammatory
response to spermatozoa after
breeding (24 h)
12 healthy mares
Experiment 1: Crossover study
Experiment 2: Two-way crossover
study
Administration of treatments,
sperm challenge and follow-up:
• Ultrasonographic
evaluations
• Lavages: PMN and cytokine
analysis
Experiment 1: 6 mares treated
with an IU infusion of:
• 20 mL of ACS in 20 mL PBS
• 20 mg of dexamethasone QS
in 20 mL PBS
• Control: 20 mL PBS
One treatment per estrous in the
same mares (every 3 weeks).
Experiment 2: 6 mares treated
with an IU infusion of:
• 20 × 106 allogeneic
BM-MSCs in 20 mL LR
• 20 mL PBS
One treatment per estrous in the
same mares (every 3 weeks).
BM-MSC and ACS were able to
modulate the uterine
inflammatory response to
spermatozoa in normal mares
Decreased neutrophil migration
into the uterine lumen in response
to insemination after BM-MSC




Healthy mares (proof of
concept for
PBIE-affected mares).
Same mares used for
different treatments.
Age of mares not stated.
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Table 2. Cont.
Pathology Study Type of MSCs Experimental Design Administration Regime Outcome Considerations






AT-MSCs and eMSCs from the
same donors in vivo in mares
with induced PBIE.
9 healthy mares with induced
PBIE.
Follow-up:
• Lavages: cytokine and gene
expression analysis
• Uterine biopsies
2 × 107 AT-MSCs (n = 3) or eMSCs
(n = 3) in 20 mL of NaCl 0.9%
Control group (n = 3): 20 mL NaCl
0.9%
Both MSC types significantly
reduced inflammation and
showed limited engraftment,
detectable after one month of
infusion
Decrease in IL-6 and TNFα in
both MSC-treated groups over
control.
Age of mares not stated.






et al., 2016 [67]
Autologous
BM-MSCs
Evaluate the feasibility and safety
of MSC endometrial injections
16 mares (15–24 years) with
reproductive history of subfertility
and endometrial degeneration






12 endometrial injections of 1 ×
106 MSCs in 0.5 mL PBS, each one
at 12 different sites, 1 cm apart
from one uterine horn to another
(12 × 106 MSCs in total)
Neither clinical alteration nor
intrauterine fluid and endometrial
edema were observed after MSC
administration.
No histological worsening
The results suggest that the
procedure is safe










Evaluate the feasibility of an MSC
delivery system for
endometrosis-affected mares.
6 mares (6–21 years) with varying
degrees of naturally occuring
endometrosis
Follow-up:
• Uterine biopsies 7, 21 and 60
days
20 × 106 AT-MSCs in 20 mL NaCl
0.9% inoculated into uterus using
a technique similar to AI
Control (n = 2): 20 mL NaCl 0.9%
Migration of AT-MSCs to the
uterine body and both horns.
Engraftment in both glandular
and periglandular spaces in three
mares.
AT-MSCs beneficially modulated








Animals 2021, 11, 931 11 of 28
Table 2. Cont.









injection of BM-MSCs improves or
restores ovarian function in aged
mares
8 aged mares (20–29 years old)
and 6 young mares (7–12 years
old)
Assessment (aged and young
mares):
• Antral follicle count
• Serum AMH
• Assessment (aged mares
only):
• Oocyte meiotic and
developmental competence
• Gross and histological
ovarian assessment
• Gene expression in ovarian
tissue as assessed by RNA
sequencing.
2 intraovarian injections of 10 ×
106 BM-MSCs (different donors)
in 1mL (95%FBS and 5%DMSO) in
four different locations per ovary
Aged mares:
First injection
• Group 1 (n = 3): BM-MSCs
from donor A
• Group 2 (n = 3): BM-MSCs
from donor B
• Group 3: Control (n = 2):
95%FBS and 5%DMSO
Second injection: at 6 weeks from
different donor
Young mares:
• Group 1 (n = 2): BM-MSCs
from donor A
• Group 2 (n = 2): BM-MSCs
from donor B
• Group 3 (n = 2): Control
(95% FBS and 5% DMSO)
No adverse events after
intra-ovarian injections were
observed
Oocyte recovery on follicle
aspiration, oocyte maturation, and
blastocyst development rates after
ICSI remained unchanged in the
MSC-treated aged mares,
suggesting no
detriment of ovarian function but
neither a beneficial effect.
Injection of BM-MSCs not
associated with significant
changes in follicle number in
young mares.
No significant changes in
peripheral AMH concentrations in
aged and young mares observed,






Small size of groups
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Table 2. Cont.








Evaluate the effect of
intratesticular injection of
BM-MSCs in healthy stallions,
and its outcome on seminal
parameters and fertility
Experiment 1: 24 stallions (3–4
years)














• Insemination of six healthy
mares (8 ± 3.5 years old)
Experiment 1:
• Intratesticular injection 10 ×
106 BM-MSCs in PBS in 5
different points (1 mL in
each point) (n = 12)
• Same injections with 5 mL
PBS (n = 12)
Experiment 2 (n = 3):
• Intratesticular injection 20 ×
106 BM-MSCs in PBS in 5
different points (1 mL in
each point)
Experiment 1: No signs of
inflammation.
No differences on testicular
volume, parenchyma echogenicity,
testicular blood flow and serum
testosterone levels between
treated and control at 24 h and 28
h.
Experiment 2: no physical
alterations or changes in sperm
parameters. Satisfactory fertility
rate (83%; 5/6) after AI.
The results suggest that MSC
intra-testicular administration






Absence of control group
in experiment 2
Small size of group in
experiment 2
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4. Application of Equine MSCs in Metabolic Disorders
Equine Metabolic Syndrome
Equine metabolic syndrome (EMS) is an endocrine disorder characterized by patho-
logical obesity, insulin dysregulation, altered hepatic function, and predisposition to de-
veloping laminitis. Obesity is the main risk factor for EMS, because adipose tissue acts as
an important secretory organ producing different molecules such as pro-inflammatory cy-
tokines with associated adverse local and systemic effects [81]. Management of EMS should
include a well-balanced diet and physical activity. Some drugs such as metformin can
help regulate this disorder, although there are no treatments available that can effectively
resolve the EMS [82].
Therefore, MSCs have been proposed as a therapeutic strategy in different metabolic
syndromes in several species, such as rodents [83–85], dogs [86] and monkeys [87]. Impor-
tantly, great attention has been paid to MSC treatment of human diabetes type 2 [88,89].
Thus, the One Medicine concept applies in both directions; knowledge from human studies
is also highly valuable for veterinary medicine.
Adipose-derived MSCs from EMS-affected horses display senescent phenotype, in-
creased apoptosis, and reduced viability and differentiation capacity, which would make
autologous therapy suboptimal [90–92]. In a recent study of the same group, autologous
AT-MSCs were exposed in vitro to pharmacotherapy with 5-azacytidine (AZA) and resver-
atrol (RES) before their clinical application in order to reverse the aged phenotype of these
cells. These rejuvenated autologous AT-MSCs showed in vivo potential to improve liver
metabolism in one EMS-diagnosed horse, as demonstrated by a decrease in specific liver
enzymes. Nonetheless, MSC therapy was combined with conventional EMS management,
which could have also contributed to this improvement [93].
5. Application of Equine MSCs in the Respiratory System
Equine Asthma
Equine asthma syndrome encompasses a spectrum of inflammatory airway diseases
characterized by chronic respiratory signs ranging in severity that can significantly affect
athletic performance [6]. Although its exact etiopathogenesis remains incompletely de-
fined, immune-mediated responses are involved and lead to excessive mucus production,
neutrophilic accumulation, bronchial hyperreactivity, and bronchospasm [94]. Treatment
is limited to environmental management, anti-inflammatory drugs, and bronchodilator
therapy. Nevertheless, the use of inhaled corticosteroids may be contraindicated in some
cases, and may also be cost-prohibitive and inconvenient for some owners [6].
Studies in murine models of induced asthma have shown that MSCs may be beneficial
for managing this process [32,95,96]. To date, there are no published reports on the use
of MSCs in vivo to treat equine asthma. However, the use of cell derivatives has been
tested. An in vitro assay showed the ability of conditioned medium and microvesicles
from equine amniotic mesenchymal cells to modulate lipopolysaccharide (LPS)-stimulated
equine alveolar macrophages, suggesting that these products can play a role in treating
inflammatory diseases of the lung [97]. In vivo, the intra-tracheal instillation of autologous
bone marrow-derived mononuclear cells in eight asthma-affected horses showed that the
procedure is safe and improved clinical signs, suggesting amelioration of the asthmatic
inflammatory response [98].
Moreover, equine and human asthma syndromes share several features, with the
difference that the process is dominated by neutrophils in horses and by eosinophils in
humans [6]. The similarities in the airway remodeling processes make equine asthma an
ideal model to study the cellular and molecular pathways associated with the asthmatic
airway response and its reversibility [10].
6. Application of Equine MSCs in Disorders of the Integumentary System
The main findings of in vivo studies using MSCs for integumentary-related disorders
are highlighted in Table 3.
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6.1. Wounds
Due to their “flight” instinct in response to frights, horses are particularly susceptible
to trauma [99]. Actually, wound injuries are the most common medical condition affecting
horses [100,101]. Traumatic wounds commonly occur in the distal limb, where healing is
often delayed due to high skin tension, minimal vascularization, and a low-grade inflamma-
tory response. This aberrant inflammation leads to a fibroproliferative response, resulting
in a dysplastic healing with exuberant granulation tissue [102]. These particularities make
successful wound management difficult, to which MSCs could contribute owing to their
varied paracrine activities.
In vitro, equine MSCs promote dermal wound repair through the mobilization of
dermal fibroblasts and by increasing the expression of genes involved in wound heal-
ing [103]. In an equine distal limb wound model using six horses, allogeneic umbilical
cord blood-derived MSCs (UCB-MSCs) were applied after culture in normoxic or hypoxic
conditions, either directly injected into wound margins or topically applied embedded in
an autologous fibrin gel. Early healing was enhanced, with histology suggesting a pro-
healing rather than a pro-inflammatory scenario and smaller sizes in MSC-treated wounds,
with no additional advantage of hypoxic preconditioning [104]. Systemic administration
of allogeneic UCB-MSCs resulted in engraftment into induced wounds on the forelimb
and thorax at early stages, without clinically adverse reactions [105]. Autologous PB-SCs
injected both locally and systemically in four naturally occurring chronic dermal wounds
in the metatarsus, unresponsive to conventional treatments, showed positive outcomes
with granulation tissue formed within four weeks, and no adverse effects were noted [106].
These results suggest MSCs as a promising tool to improve and accelerate the healing of
chronic wounds.
Equine distal limb wounds display similarities to human wounds, with keloid forma-
tion in the latter being similar to exuberant granulation tissue formation in horses. Humans
and equines are the only two species that spontaneously develop these fibroproliferative
disorders, making the horse a suitable model for studying the pathogenesis and treatment
of keloids and hypertrophic scars [99]. In both species, chronic wound management is a
growing problem leading to a significant economic impact; thus, there are demands for
advanced therapeutic options able to decrease healing time and minimize complications.
6.2. Decubitus Ulcers
Decubitus ulcers result from pressure, shear, and/or friction when the patient is lifted
or put in decubitus, leading to tissue ischemia, cell death and necrosis [107]. Thus, the
pathogenesis of this injury differs from that in traumatic wounds. Neonatal foals are prone
to decubitus ulcers due to their thin skin and possible concomitant disorders, which force
them into prolonged decubitus [108]. Mesenchymal stem cells play a key role in skin
homeostasis and repair by promoting cell differentiation, immunomodulation, and the
secretion of growth factors to drive re-epithelialization and neovascularization [109].
In a septic neonatal foal, local implantation of amniotic fluid-derived MSCs (AF-
MSCs) along with platelet-rich plasma (PRP) gel effectively improved decubital ulcers
earlier than in those ulcers treated with Aloe vera gel only [110]. In another study, several
deep sore wounds, presented concomitantly in five septic foals, were treated by either
allogeneic AF-MSCs embedded in a carboxymethylcellulose scaffold or by a commercial
preparation of formosulfathiazole, the former leading to faster healing [111]. Additionally,
the effectiveness of local application of allogeneic Wharton’s jelly MSCs (WJ-MSCS) was
reported in a six-month-old filly with a large non-healing skin wound in the hock [112].
Therefore, MSCs may be considered for healing skin ulcers in foals, with no side effects
noticed, although data are limited to a few reports including low numbers of animals.
6.3. Laminitis
Laminitis is included as part of the integumentary system provided the distal third
phalanx is enveloped by a specialized epithelial tissue, the corium, attaching the bone to the
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hoof. However, it should be noted that this is a complex and multifactorial disease [113].
This disorder affecting the hooves of ungulates is of particular importance in equids,
carrying a poor prognosis, with a strong economic impact and constituting a serious issue
for animal welfare that may eventually require euthanasia [114]. A great variety of initiating
causes can lead to the onset of the disease and can be influenced by different body systems,
including inflammation, metabolic disorders, and endothelial or vascular dysfunction [113].
Whatever the triggering factors are, the release of pro-inflammatory mediators and the
activation of metalloproteinases leads to the degradation of the basement membrane that
may result in a complete mechanical collapse of the foot [115].
The largely incomplete knowledge of the pathogenic mechanisms involved in laminitis
makes both prevention and treatment difficult [116]. Laminitis has been associated with
the loss of p63+ epidermal stem cells in the hoof lamellae, suggesting limited proliferative
potential of the laminitic hoof epithelium [117]. Therapy with MSCs is a promising tool to
improve cell proliferation and tissue quality, as well as contribute to vascular stabilization
and control the pro-inflammatory environment.
In clinical studies on chronic refractory laminitis, allogeneic UCB-MSCs were delivered
directly to the affected foot via regional perfusion (digital vein). The outcome suggested a
positive MSC effect on the prognosis of animals treated early, as reflected by the evolution
with decreased radiologic distance between the bone and hoof wall [114,118]. Allogeneic
BM-MSCs provided better results when digitally perfused compared to epidermally in-
jected [119]. Another study on chronic laminitis administered allogeneic and autologous
AT-MSCs suspended in autologous PRP by distal digital venous injection. Improvement of
both hoof quality and animal mobility was reported, improving the life quality of treated
horses [120].
These results encourage further exploring the use of MSCs to treat chronic laminitis,
but it is important to highlight that MSC administration does not eliminate the need for
routine management and appropriate hoof support.
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Table 3. In vivo studies using mesenchymal stem cells for integumentary system disorders. Umbilical cord-derived stem cells (UCB-MSCs), transforming growth factor beta (TGF-β),
cyclooxygenase-2 (COX-2), intravenous (IV), HypoThermosol FRS (HTS-FRS), peripheral blood stem cells (PB-SCs), phosphate-buffered saline (PBS), amniotic fluid MSCs (AF-MSCs),
platelet-rich plasma (PRP), carboxymethylcellulose (CMC), Wharton’s jelly MSCs (WJ-MSCs), bone marrow mesenchymal stem cells (BM-MSCs), adipose tissue MSCs (AT-MSCs).







Six horses (3 mares, 3 geldings;
5–19 years)
Induced model: 3 full-thickness
cutaneous wounds surgically
created on each distal forelimb
Assessment and follow-up (6
weeks):




10–20 × 106 normoxic UCB-MSCs,
hypoxic UCB-MSCs or control in 1
mL NaCl 0.9% were injected into
wound margins or topically
applied embedded in an
autologous fibrin gel, 1 day after
wound creation
MSC administration by either
delivery method was safe and
improved histologic outcomes




gel-treated or control wounds.
Hypoxic pre-conditioned MSCs
did not provide a substantial
advantage
Treatments applied very
early and in aseptically








Determine adverse reactions after
IV MSC administration and assess




created on the left lateral third
metacarpus (7 wounds) and left
hemi-thorax (7 wounds)
1.02 × 108 UCB-MSCs
(fluorescently labelled) in 60 mL
HTS-FRS via IV administration
Control: 2 wounds were left to
heal by second intention (in the
same horses)
No clinically adverse effects
(largest recorded dose of IV
UCB-MSCs)
UCB-MSCs preferentially
engrafted into wounds during the
acute and early remodeling
phases.Results suggest no
difference in homing potential
between limb and thoracic
wounds
Low number of animals




to the sequential control
site (untreated control
not included)
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Table 3. Cont.
Pathology Study Type MSCs Experimental Design Administration Regime Outcome Considerations
Traumatic




4 horses with naturally occurring
traumatic wounds unresponsive
to conventional therapies for at
least 3 months:
• Case 1 (11-year-old mare):
dorsal surface of the
metatarsal bone infected
with Clostridium spp.
• Case 2 (16-year-old gelding):
plantar surface of the
metatarsal bone infected
(presence of pus)
• Case 3 (26-year-old gelding):
deep wound with bone
exposition at the medial
surface of the tibia
• Case 4 (26-year-old gelding):
wound presenting
non-neoplastic exuberant
granulation tissue on the
plantar surface of the
metatarsal bone. Nodular
proliferative lesions recurred
after resection and tended to
ulcerate.
5 × 105 PB-SCs in 2 mL PBS were
locally (intradermally) injected
into 5–6 different locations at the
wound’s edges and 1.25 × 105
PB-SCs via IV administration
Granulation tissue began forming
within 4 weeks of the PB-SC
therapy in cases 1, 2 and 3. Crust
formation was achieved within 2
months.
In case 4, the granulation tissue
could be easily removed without
recurrence of the wound.
1 year: no wound recurrence or
other adverse effects
Low number of cases of
varying presentation
with no control group,
but unresponsive to
previous treatments.
Cells used not expanded
and not fully
characterized as MSCs.




each individual case is
not deeply explained
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One septic neonatal foal with
severe ulcers in fetlocks, carpus
and right stifle
• Aloe gel every 48 h: Left
hock and carpus
• 10 mL PRP gel: right carpus
• 5 × 106 AF-MSCs + 10 mL
PRP gel (twice a week for 2
weeks): right hock
None of the wounds treated
developed exuberant scar tissue
Healing was faster using
AF-MSCs + PRP. The ulcer treated
this way resulted in a linear scar,
while the other lesions produced
star scars
7 months: ulcer treated with aloe












5 hospitalized neonatal foals
(10–15 days old) with a total of 9
pressure sores on the carpus (4),
fetlock (2), and hock (3). Sores
were divided into group 1 (n = 6)
and group 2 (n = 3)
• Group 1: 5 × 105 AF-MSCs
in CMC gel applied twice a
week for 2 weeks
• Group 2: formosulfathiazole
ointment every 48 h
Sores treated with AF-MSCs in
CMC gel healed quicker
30 days: no further treatments
were needed











hospitalized by the re-injury of a
pressure wound on the left hock
5 × 106 WJ-MSCs in a CMC gel
were applied every 4 days for 4
times
Four days after the last
application, no further bandages
were applied and the wound was
daily cleaned and treated with
hydrotherapy (cold tap water 10
min/day)
No side effects and fast wound
regression
No evident exuberant scar.
The hair grew completely without
changing color80% regression rate
between 8 days and 39 days
No relapse
One single case with no
control
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Table 3. Cont.






12 horses with naturally occurring
chronic laminitis unresponsive to
other treatments
20–25 × 106 UCB-MSCs in NaCl
0.9% infused by regional
perfusion (digital vein) every 3–4
weeks (3 infusions in total per
affected foot)
83% of horses with positive





still need to be
determined
Only clinical follow-up
Absence of control group








30 horses with naturally occurring
chronic laminitis
20–30 × 106 allogeneic UCB-MSCs
in NaCl 0.9% infused by regional
perfusion (digital vein) and
subsequent injections with either
20–30 × 106 autologous BM-MSCs
or allogeneic UCB-MSCs
(4 infusions in total at 1 month
intervals)
21 patients (70%): successful
outcome.
Decreased radiologic distance
between the bone and hoof wall
Cases receiving MSCs < 30 days
after the onset of laminitis:
success rate was 100%.
Cases receiving MSCs > 90 days
after the onset of laminitis:
success rate was 50%.
Results suggest improved
prognosis in cases treated early.
Routine treatments for
laminitis continued













9 horses (5 mares, 4 geldings;
10–21 years) with severe naturally
occurring laminitis unresponsive
to conventional therapies
15 × 106 allogeneic AT-MSCs in
15 mL autologous PRP infused by
regional perfusion (digital vein)
and subsequent injections with
autologous AT-MSCs (3 infusions
in total at 1 month intervals)
Clinical and radiologic signs
improved
All the animals returned to
activity at six months from the
first treatment.
12 months: 7 horses still
performing activity
24 months:
• 2 animals relapsed and were
euthanized
• 3 horses deceased (unrelated
to laminitis)
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7. Application of Equine MSCs in Neurological Disorders
Neurological disorders affecting the brain and spinal cord can represent a therapeutic
challenge, and many horses can have sequelae even after recommended treatment [121].
The neuroprotective effects of MSCs have been described in other species and involve anti-
inflammatory, immunomodulatory, pro-angiogenic and trophic mechanisms [122,123], which
could ameliorate the symptoms of several neurodegenerative disorders [124]. Furthermore,
MSCs can trans-differentiate in vitro into neuronal lineages [125]. In vivo related studies in
horses are summarized in Table 4.
7.1. Peripheral Nerve Injury
Horses suffer injury to peripheral nerves from trauma, metabolic and genetic disorders,
toxins or degenerative and infectious diseases [126]. The degree of restoration of nerve
function depends on the severity and chronicity of the damage, with the worst prognosis
in cases where the nerve is transected [127]. There are few surgical techniques for repairing
nerves, and clinical results are often poor [128]. Consequences frequently include poor
performance, disability, or even death [129,130].
In an in vivo model of acute peripheral nerve injury using three horses, allogeneic BM-
MSCs were implanted into the fascia surrounding the ramus communicans of one forelimb
after a portion was transected. No evidence of nerve regeneration was observed, neither
were histological differences between MSC-treated and control injuries found 45 days
later [127]. Nevertheless, improvement of nerve regeneration after MSC treatment has been
observed in other large animals such as sheep [131].
7.2. Wobblers Syndrome
Wobblers syndrome, also known as cervical vertebral stenotic myelopathy (CVSM)
or incoordination syndrome, is characterized by ataxia and weakness, caused by the
narrowing of the cervical vertebral canal and/or compression of the spinal cord. Medical
treatment commonly includes steroidal and nonsteroidal anti-inflammatory drugs, along
with diet and exercise restrictions. Surgery can be considered in some cases, but this option
is expensive and involves significant risks [132].
An intrathecal injection could extensively deliver cells through the cerebrospinal
fluid to reach the equine central nervous system. To evaluate the feasibility and safety of
intrathecal transplantation of cells, autologous BM-MSCs were administered to healthy
horses and no clinical alterations were developed [133]. A posterior study aimed at
determining the safety of a relatively high dose of intrathecal allogeneic AT-MSCs in both
healthy and CVSM-affected horses. Neurological status was not altered regardless of
atlanto-occipital or lumbosacral administration. Atlanto-occipital injection is apparently
distributed more efficiently through the subarachnoid space, suggesting that this approach
might be more suitable for cranial spinal cord lesions. As for diseased horses, MSCs could
not be found at 15 days after injection at the site of injury, so either cells did not reach the
lesion site or did not persist at that time [134].
7.3. Laryngeal Hemiplegia or Left Recurrent Laryngeal Neuropathy
Recurrent laryngeal neuropathy is characterized by varying degrees of arytenoid
paralysis, constituting a highly prevalent pathology of the upper airway in horses [135].
Affected horses emit abnormal respiratory sounds and may present exercise intolerance in
severe cases. Although the overall success rate of laryngoplasty with or without ventriculo-
cordectomy is elevated, post-operative complications such as a gradual loss of abduction
are very common [136].
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Table 4. In vivo studies using mesenchymal stem cells in equine neurological disorders. Bone marrow mesenchymal stem cells (BM-MSCs), adipose tissue MSCs (AT-MSCs), cervical
vertebral compressive myelopathy (CVCM), 99m technetium-hexamethyl-propylene-amine-oxyme (99mTc-HMPAO), atlanto-occipital (AO), lumbosacral (LS), recurrent laryngeal
neuropathy (RLN), muscle-derived MSCs (M-MSCs).








Induced model: 3 healthy
mares (9–13 years old) with
surgically created 15-mm
longitudinal incision over the
ramus communicans
10 × 106 BM-MSCs in 1
mL NaCl 0.9% or 1 mL
NaCl 0.9% (control)




communicans of each fore
limb were harvested 45
days after treatment or
control administration
No evidence of nerve regeneration
No histological differences between MSC-treated
and control nerve stumps
No histological evidence of BM-MSCs or

















assessment in 6 healthy mares
(6–21 years) and 3 diseased










Healthy horses: 100 ×
106 AT-MSCs in 5 mL
NaCl 0.9% were injected
either AO (n = 3) or LS (n





injected with free label
as a control.
Diseased horses: 100 ×
106 AT-MSCs via AO
Healthy horses:
AO and LS intrathecal injection of relatively high
doses of AT-MSCs was well tolerated
AT-MSCs apparently distributed more efficiently
through the subarachnoid space after AO
injection (suggested as preferred route to deliver
MSCs to the cervical area)
Diseased horses:
AT-MSCs not found at 15 days after injection at
the site of injury (either did not have time to
reach the lesion site or did not survive long
enough)
No horses developed detectable anti-AT-MSC
alloantibodies.
Low number of horses
per group.
Tracking and control







5 healthy mares (ages 10–22)
Evaluate the feasibility and
safety of administering MSCs
by a peri-neural injection to
the left recurrent laryngeal
nerve in healthy horses by
using an electrical nerve
stimulator





nerve by a nerve
stimulator-guided
injection
Feasibility and safety of the procedure suggested
by absence of functional changes upon
endoscopic evaluation up to 28 days.
No signs of adverse events in four out of the five
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To explore the feasibility of using MSCs to promote nerve function restoration, a nerve-
stimulator-guided injection of muscle-derived autologous MSCs near the left recurrent
laryngeal nerve was performed in five healthy horses. Laryngeal function was not affected,
thus suggesting that this delivery technique is safe [137]. These findings would facilitate
future studies assessing MSC effectiveness to treat this pathology, which has not yet been
tested, to the best of the authors’ knowledge.
8. Application of Equine MSCs in Endotoxemia
Systemic inflammatory response syndrome (SIRS) is characterized by an exaggerated
inflammatory response to an aggression, which causes a series of unspecific clinical signs
that can seriously compromise the patient’s life. This process is of great importance in
horses due to the particularities of their inflammatory response and the high incidence
of pathologies such as acute abdominal syndrome, pneumonia, and metritis, which can
provoke an endotoxemia or sepsis and subsequent SIRS development. These processes can
lead to complications such as disseminated intravascular coagulation, vascular endothelial
damage, laminitis, and multiple organ dysfunction syndrome [138]. Therefore, SIRS is
associated with a significantly higher risk of death in horses presenting acute colic [139] or
other disorders. There are no specific treatments for endotoxemia and SIRS other than con-
trolling the primary cause and providing supportive therapy, mostly based on fluids and
antiendotoxics [138]. The complexity and poor prognoses of these processes and the lack
of effective treatments have led to the interest in using MSCs because of their immunomod-
ulatory capacity. Actually, there are a number of studies in rodent models of endotoxemia
showing promising results of the administration of MSCs, including decreased levels of
circulating proinflammatory cytokines and increased survival rates [140].
In horses, and to the best of the authors’ knowledge, there is only one study reporting
the effects of administering MSCs in an experimental model of endotoxemia [141]. In this
study, lipopolysaccharide was IV injected into six horses, and three of them immediately
received 100 × 106 allogeneic BM-MSCs IV. Serial clinicopathological assessment and de-
termination of pro-inflammatory cytokine production did not show significant differences
between treated and control animals, but adverse reactions after MSC infusion were not
observed either, thus suggesting that the procedure is safe; however, further studies with
higher numbers of animals and studying variables such as the dosage and moment of
administration are needed to elucidate the potential benefit of this therapy. Importantly,
endotoxemia, sepsis, and SIRS also affect a high percentage of human patients in intensive
care units, and the horse has been proposed as a model for understanding human innate
immunity and shedding light onto pathology processes and therapeutics [142].
9. Conclusions and Future Perspectives
The unique properties of MSCs hold a great potential for the treatment of different
equine diseases other than musculoskeletal injuries, for which current pharmacologic or
surgical approaches often do not provide satisfactory results.
Several studies have explored the use of MSCs for different equine diseases beyond
the locomotor system. Their application for ophthalmologic and reproductive disorders
has been particularly investigated, and the treatment of wounds, asthma, and SIRS holds
a special interest to develop One Medicine approaches. However, the variability among
clinical case conditions, source of the MSCs used, cell isolation and culture techniques, and
therapeutic protocols (MSC dose, route, number, and frequency of administrations), as well
as the low sample size and lack of control groups in some of the studies, limit extracting
definitive conclusions. Nevertheless, case reports are highly valuable as a proof of concept,
indicating that there is potential for in further investigations. In addition, in vitro studies
provide interesting preliminary insight into MSC mechanisms for each pathology, and
in vivo studies in healthy animals enable safety and feasibility assessments.
More in-depth research is needed to test the safety and efficacy of these novel treat-
ments, and future clinical trials would include a larger number of similar cases and stan-
Animals 2021, 11, 931 23 of 28
dardized measurements of the outcomes, in order to establish specific therapeutic protocols.
Furthermore, more in vitro and experimental work is needed to understand the pathways
through which MSCs elicit their effects, in order to achieve their highest therapeutic poten-
tial. Therefore, researchers and clinicians should work together to develop evidence-based
treatments and exploit the MSC potential by extending their use to different pathologies in
both equine and human patients.
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